NAOR is a platform for rapid RNA diagnosis of COVID-19 and other pathogens. The company uses a one-step nucleic acid amplification method to multiply specific sequences of RNA, resulting in extremely high sensitivity and specificity. The technology enables high-volume lab-grade results in field settings such as airports, schools, and workplaces. The tests can also be conducted at home.
Originally developed at the Technion, the technology combines biochemistry, electronics, and artificial intelligence. The original clinical study (with results from Rambam Medical Center) was one of the first to use rapid RNA testing of the virus. The company has since gathered significant data from around the world and further developed the technology. Its platform is now available in select markets worldwide.
NAOR is developed by Rapid Diagnostic System Ltd.
Cumulative Funding Raised Over Time ($)
Employees Over Time
NAOR Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Sep 22, 2020
www.timesofisrael.com
Israel will soon be able to test hundreds of thousands daily, scientist claims
#Customers
Sep 22, 2020
www1.cbn.com
Israeli Team Developing At-Home Coronavirus Test With Results in Less Than an Hour
#Customers
Sep 22, 2020
www.prnewswire.com
Direct On-the-Spot Detection of SARS-CoV-2 in Patients
#Customers
Sep 22, 2020
www.haaretz.com
Israeli researchers developing home test kit for coronavirus
#Customers #Partners
Sep 22, 2020
www.timesofisrael.com
Technion researchers create rapid home testing kit for coronavirus